1h Free Analyst Time
The gastroparesis drugs market is forecasted to grow by USD 1.42 billion during 2023-2028, accelerating at a CAGR of 3.69% during the forecast period. The report on the gastroparesis drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising global burden of diabetes, increasing prevalence of gastroparesis, and increasing awareness about gastroparesis.
The gastroparesis drugs market is segmented as below:
By Drug Class
- Prokinetic agents
- Antiemetics
- Botulinum toxin injection
By Disease Type
- Idiopathic gastroparesis
- Diabetic gastroparesis
- Post-surgical gastroparesis
By Geography
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the gastroparesis drugs market covers the following areas:
- Gastroparesis drugs market sizing
- Gastroparesis drugs market forecast
- Gastroparesis drugs market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Drug Class
7 Market Segmentation by Disease Type
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
List of Exhibits
Executive Summary
The publisher recognizes the following companies as the key players in the global gastroparesis drugs market: Abbott Laboratories, AbbVie Inc., Aclipse Therapeutics, ANI Pharmaceuticals Inc., Bausch Health Companies Inc., Cadila Pharmaceuticals Ltd., Eisai Co. Ltd., Evoke Pharma Inc., GlaxoSmithKline Plc, Ipca Laboratories Ltd., Johnson and Johnson, Medtronic Plc, Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Processa Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., Theravance Biopharma Inc., Vanda Pharmaceuticals Inc., and Neurogastrx Inc..Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is increasing growth opportunities in emerging markets.'
According to the report, one of the major drivers for this market is the rising global burden of diabetes.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Aclipse Therapeutics
- ANI Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Cadila Pharmaceuticals Ltd.
- Eisai Co. Ltd.
- Evoke Pharma Inc.
- GlaxoSmithKline Plc
- Ipca Laboratories Ltd.
- Johnson and Johnson
- Medtronic Plc
- Otsuka Pharmaceutical Co. Ltd.
- Pfizer Inc.
- Processa Pharmaceuticals Inc.
- Rhythm Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- Theravance Biopharma Inc.
- Vanda Pharmaceuticals Inc.
- Neurogastrx Inc.
